Welcome, Guest. Please Login or Register
Clusterheadaches.com
 
Search box updated Dec 3, 2011... Search ch.com with Google!
  HomeHelpSearchLoginRegisterEvent CalendarBirthday List  
 





Page Index Toggle Pages: 1
Send Topic Print
Potential new CH and migraine preventive (Read 836 times)
Mike NZ
CH.com Hall of Famer
*****
Offline


Oxygen rocks! D3 too!


Posts: 3785
Auckland, New Zealand
Gender: male
Potential new CH and migraine preventive
Jun 10th, 2017 at 1:09am
 
Multimedia File Viewing and Clickable Links are available for Registered Members only!!  You need to Login or Register

Quote:
INDIANAPOLIS, June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from 14 abstracts, including late-breaking Phase 3 data for two investigational treatments for migraine, at the American Headache Society (AHS) annual scientific meeting, taking place June 8-11 in Boston.

Lilly will highlight new, Phase 3 primary and secondary endpoint data in three late-breaking presentations for galcanezumab for the prevention of episodic and chronic migraine. Galcanezumab is a once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) antibody currently being studied as a potential treatment for the prevention of migraine and cluster headache.

Lilly will also present late-breaking Phase 3 data from a study evaluating the efficacy and safety of lasmiditan for the acute treatment of migraine. Lasmiditan is an oral, first-in-class molecule that could represent the first significant innovation for the acute treatment of migraine in more than two decades.

"For more than 25 years, Lilly's expert clinicians and researchers have worked to develop innovative treatments that can improve the lives of patients with migraine and address the challenges healthcare providers face in treating this serious disease," said Robert Conley, M.D., Distinguished Lilly Scholar, neuroscience. "We are truly excited to present a range of new data from our migraine portfolio, which support the potential use of both galcanezumab and lasmiditan as much-needed, new treatment options for patients suffering from migraine."


Good to see that new research is ongoing with trials not just for migraine but also for CH. Hopefully this has the potential to help even more people with both these conditions.
Back to top
  
 
IP Logged
 
Page Index Toggle Pages: 1
Send Topic Print

DISCLAIMER: All information contained on this web site is for informational purposes only.  It is in no way intended to be used as a replacement for professional medical treatment.   clusterheadaches.com makes no claims as to the scientific/clinical validity of the information on this site OR to that of the information linked to from this site.  All information taken from the internet should be discussed with a medical professional!